[7] [8] A research-grade COA does not prove human safety, clinical effectiveness, sterility, endotoxin control, or suitability for any non-research use
This especially occurs when they hear about Semaglutide weight loss results and Tirzepatide weight loss results
doi: 10.3390/ijms14023265 115 LinJLiuFZhangYYSongNLiuMKFangXYet al
Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies
Ania Jastreboff, MD, PhD, Yale School of Medicine, lead author of SURMOUNT-1 [1] This dual-action approach is why providers frequently prescribe them together rather than individually